ToddLouisRosenblatMD

Hematologic Oncology

Assistant Professor of Medicine at Columbia University Medical Center, Div. of Hematology/Oncology New York-Presbyterian Hospital/Columbia University Medical Center

Request Appointment

Overview of Dr. Rosenblat

Dr. Todd Rosenblat is a hematologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, NewYork-Presbyterian/Columbia University Irving Medical Center, and Memorial Sloan Kettering Cancer Center. He received his medical degree from Stony Brook University Health Sciences Center School of Medicine and has been in practice 14 years. Dr. Rosenblat accepts several types of health insurance, listed below. He is one of 61 doctors at Memorial Sloan Kettering Cancer Center and one of 64 doctors at New York-Presbyterian Hospital who specialize in Hematology. He has more than 20 publications and over 500 citings.

Office
622 W 168th St
New York, NY 10032
Book by Phone+1(505) 386-4204

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
NYU Grossman School of MedicineResidency, Internal Medicine, 2003 - 2006
Stony Brook University Health Sciences Center School of MedicineClass of 2003

Certifications & Licensure

NY State Medical License 2004 - 2026
American Board of Internal Medicine Hematology

Clinical Trials

Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML) Start of enrollment: 2010 Jun 01
Completed
Phase 3
Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia Start of enrollment: 2012 Dec 13
Completed
Phase 3

Publications & Presentations

PubMed

7 citations
A Transcriptome-Based Precision Oncology Platform for Patient-Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies.
Prabhjot S Mundi, Filemon S Dela Cruz, Adina Grunn, Daniel Diolaiti, Audrey Mauguen
Cancer Discovery. 2023-06-02
1544 citations
CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
Renier J. Brentjens, Marco L. Davila, Isabelle Riviere, Jae H. Park, Xiuyan Wang
Science Translational Medicine. 2013-03-20
103 citations
Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia.
Peter Maslak, Tao Dao, Yvette Bernal, Suzanne Chanel, Rong Zhang
Blood Advances. 2018-02-13

Abstracts/Posters

Combination Thioguanine and Decitabine Is Highly Active in Patients with Advanced Myeloid Malignancies: A Single Institution Experience
Todd L. Rosenblat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best...
Todd L. Rosenblat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration t...
Todd L. Rosenblat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediat...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment